Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.


Expert Opinion / Cases · June 11, 2021

Patient With mCRPC With BRCA1+ and High Tumor Mutational Burden

Written by
Pedro C. Barata MD


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Noureddine Benjaafar

    Jun 12, 2021


  • Charles Maack

    Jun 12, 2021

    Olaparib, but if not effective, Docetaxel plus carboplatin

  • Noureddine Benjaafar

    Jun 12, 2021

    Olaparib because of BRCA1 mutation 

  • phil capozzi

    Jun 18, 2021

    Olaparib for BRCA mutation

  • Syamsu Hudaya

    Jun 20, 2021


  • Prasanta Kumar Pradhan

    Apr 02, 2022


  • Mar 03, 2024

    Pending Moderator approval.

Further Reading